Otrivine Extra Dual Relief Nasal Spray 10ml

• One puff in each nostril up to 3 times per day
• Leave at least 6 hours between doses
• Not more than 3 applications daily into each nostril
• The product should not be used for more than 7 days
• Always blow your nose before using the nasal spray
• Suitable for use from 18 years and older.
• Do not use for more than 7 consecutive days.

Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution. (0.5 mg/ml xylometazoline hydrochloride and 0.6 mg/ml ipratropium bromide). Indications: Symptomatic treatment of nasal congestion and rhinorrhea in connection with common colds. Dosage: 1 puff in each nostril, up to 3 times daily, with at least 6 hours between doses. Not for use longer than 7 days. Contraindications: Children and adolescents under 18 years. Known hypersensitivity to xylometazoline hydrochloride or ipratropium bromide or any excipients or hypersensitivity to atropine or similar substances. Patients with glaucoma or rhinitis sicca or following trans-sphenoidal hypophysectomy or surgery exposing the dura mater. Warnings and precautions: Use with caution in people with: hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, prostatic hypertrophy, bladder stenosis, pheochromocytoma, angle closure glaucoma, epistaxis, paralytic ileus, cystic fibrosis. Caution in people sensitive to adrenergic substances, which may cause sleep disturbances, dizziness, tremor, cardiac arrythmias or elevated blood pressure. Hypersensitivity reactions may occur. Do not use for more than 7 days. Use during pregnancy or breastfeeding only if clearly necessary. Avoid contact with eyes. Side effects: See SPC for full details. Hypersensitivity reactions (including angioedema, urticaria and bronchospasm). Localised irritation in the nose and throat, nausea, headache and dryness of the nasal mucosa. Systemic cardiovascular effects should be kept in mind in those with cardiovascular disease. In isolated cases, systemic allergic reactions, insomnia, fatigue, urine retention and transient visual disturbances. Price: £6.66 (ex. VAT) Legal Status: P. Licence Number: PL 44673/0153. Licence Holder: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, Brentford, TW8 9GS, UK. Date of revision: April 2019